ALZN — Alzamend Neuro Balance Sheet
0.000.00%
- $8.44m
- $2.82m
Annual balance sheet for Alzamend Neuro, fiscal year end - April 30th, USD millions except per share, conversion factor applied.
2021 April 30th | 2022 April 30th | 2023 April 30th | 2024 April 30th | 2025 April 30th | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Cash | |||||
Cash and Short Term Investments | 1.93 | 14.1 | 5.14 | 0.376 | 3.95 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 0.016 | 0 | — | — | — |
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 2.91 | 14.4 | 5.84 | 0.455 | 4.18 |
Net Property, Plant And Equipment | — | 0.103 | 0.08 | 0.176 | 0.426 |
Total Assets | 2.91 | 14.5 | 5.92 | 0.632 | 4.6 |
Payable / Accrued | |||||
Notes Payable / Short Term Debt | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 0.9 | 1.16 | 2.87 | 3.23 | 0.635 |
Total Long Term Debt | |||||
Total Debt | |||||
Total Liabilities | 0.9 | 1.16 | 2.87 | 3.23 | 0.635 |
Redeemable Preferred Stock | |||||
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Other Equity | |||||
Total Equity | 2.01 | 13.4 | 3.05 | -2.59 | 3.97 |
Total Liabilities & Shareholders' Equity | 2.91 | 14.5 | 5.92 | 0.632 | 4.6 |
Total Common Shares Outstanding | |||||
Total Preferred Shares Outstanding |